<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/03DFD9E5-162F-4F44-8C5D-198BF4D7C39C"><gtr:id>03DFD9E5-162F-4F44-8C5D-198BF4D7C39C</gtr:id><gtr:name>Public Health Agency of Canada</gtr:name><gtr:address><gtr:line1>130 Colonnade Road</gtr:line1><gtr:line2>A.L. 6501H</gtr:line2><gtr:postCode>K1A 0K9</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/51FAE27D-6F57-4089-98B0-E0F4BB1DE196"><gtr:id>51FAE27D-6F57-4089-98B0-E0F4BB1DE196</gtr:id><gtr:name>Piti?-Salp?tri?re Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5053B8F1-C125-4EA2-9951-1CEC5AE08D3B"><gtr:id>5053B8F1-C125-4EA2-9951-1CEC5AE08D3B</gtr:id><gtr:name>Carlo Besta Neurological Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>CJD Surveillance Unit-DCN</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/03DFD9E5-162F-4F44-8C5D-198BF4D7C39C"><gtr:id>03DFD9E5-162F-4F44-8C5D-198BF4D7C39C</gtr:id><gtr:name>Public Health Agency of Canada</gtr:name><gtr:address><gtr:line1>130 Colonnade Road</gtr:line1><gtr:line2>A.L. 6501H</gtr:line2><gtr:postCode>K1A 0K9</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/51FAE27D-6F57-4089-98B0-E0F4BB1DE196"><gtr:id>51FAE27D-6F57-4089-98B0-E0F4BB1DE196</gtr:id><gtr:name>Piti?-Salp?tri?re Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5053B8F1-C125-4EA2-9951-1CEC5AE08D3B"><gtr:id>5053B8F1-C125-4EA2-9951-1CEC5AE08D3B</gtr:id><gtr:name>Carlo Besta Neurological Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/50D9D2F7-79EB-4BF6-AF22-A1616BB1AED2"><gtr:id>50D9D2F7-79EB-4BF6-AF22-A1616BB1AED2</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Green</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ016071%2F1"><gtr:id>77A4D96B-308C-4E69-B432-E57064A2441A</gtr:id><gtr:title>Optimisation, harmonisation and standardisation of real-time QuIC analysis of CSF in the diagnosis of sporadic Creutzfeldt-Jakob disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J016071/1</gtr:grantReference><gtr:abstractText>Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare neurological disease which causes a very rapid form of dementia. Most people with the disease die within 6 months of having their first symptoms. The brains of people with sCJD are full of an abnormally twisted form of a protein called prion protein. This abnormal prion protein forms large clumps which are found throughout the brain and stop it functioning normally. The diagnosis of sCJD is made in life by doctors examining the patient for the presence of neurological features of sCJD and the results of investigations such as EEG, MRI and the presence of a protein called 14-3-3 in the fluid surrounding the brain (cerebrospinal fluid-CSF). However each of these investigations may be positive in other diseases and a definite diagnosis of sCJD can only be made by examining the brain tissue either after death or by a brain biopsy. Recently a new test, called real-time quaking-induced-conversion (RT-QuIC), has been developed which can detect the presence the abnormal prion protein in CSF. Scientific studies have shown RT-QuIC can identify patients with sCJD more accurately than CSF 14-3-3. There is a lot of interest in establishing this test in many laboratories throughout Europe and the aim of this project is to make sure that all laboratories performing RT-QuIC do it in a similar way and get comparable results. This is important as it ensures that the diagnosis of sCJD throughout Europe is as consistent as possible.</gtr:abstractText><gtr:technicalSummary>This proposal focuses on the optimisation of a recently developed analytical procedure called real-time quaking-induced conversion (RT-QuIC) which detects disease-associated prion protein in cerebrospinal fluid (CSF) of patients with sporadic Creutzfeldt-Jakob disease (sCJD). Two independent studies have shown recently that analysing CSF samples from patients with suspected sCJD using this technique has enabled those patients with disease to be identified with a high degree of sensitivity and specificity. This is a major advance in the development of a disease-specific pre-mortem diagnostic test for sCJD and there is considerable interest in establishing this test as a routine diagnostic test in Europe. It is important that RT-QuIC is optimised in terms of analytical performance and that there is a common approach to the clinical application of this technique, prior to its widespread use. It is crucial that this happens in a co-ordinated manner to ensure consistency between laboratories and that the factors affecting the test performance are thoroughly investigated. This is a focussed and well-defined project with clear objectives and is achievable within the time-frame allocated. The consortium consists of well respected scientists and clinicians who have a wealth of experience in harmonising and standardising diagnostic tests for sCJD. They are well known to each other and have collaborated closely in the past. In addition we have as advisory experts the scientists who have developed this technique to ensure that the consortium has the best possible scientific support. Once this test is harmonised and standardised across Europe it has the potential to lead to more accurate pre-mortem diagnosis of sCJD.</gtr:technicalSummary><gtr:potentialImpactText>The impact of this project will be to introduce a new diagnostic test for sporadic CJD in a standardised manner to ensure that the diagnosis and surveillance of CJD is harmonised throughout Europe.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>183632</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Carlo Besta Neurological Institute</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Neuropathology</gtr:department><gtr:description>JPND Italy1</gtr:description><gtr:id>55804C35-5C2E-4BD4-9CB1-4AEE5A09EB58</gtr:id><gtr:impact>Still collecting data</gtr:impact><gtr:partnerContribution>Collection of data that they have acquired using this technique</gtr:partnerContribution><gtr:piContribution>We have trained scientists from this organisation in the RT-QuIC technique</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health Agency of Canada</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>National Microbiology Department</gtr:department><gtr:description>JPND Canada</gtr:description><gtr:id>DCA4B957-9DFF-45C1-BB9D-5BE6E9C919EB</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Supply of data using above materials with RT-QuIC</gtr:partnerContribution><gtr:piContribution>Supply of CSF and recombinant proteins for the use of RT-QuIC</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>JPND Germany</gtr:description><gtr:id>C1F9A878-72D6-4532-8C6B-652F66DD4D8F</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:partnerContribution>Collection of data acquired by RT-QuIC</gtr:partnerContribution><gtr:piContribution>Training of scientific staff in the RT-QuIC technique</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>University Hospital Antwerp</gtr:department><gtr:description>JPND Belgium</gtr:description><gtr:id>EEAA1403-796C-453C-9F35-8CC3080F2124</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Our partners in Belgium have contributed to our collaboration by analysing blinded CSF samples by RT-QuIC as part of a European-wide harmonisation of RT-QuIC.</gtr:partnerContribution><gtr:piContribution>We have trained clinical scientists in the RT-QuIC technique. We have supplied recombinant PrP and CSF samples for the establishment of RT-QuIC in Belgium</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Piti?-Salp?tri?re Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Alzheimer's and Prions Diseases Laboratory</gtr:department><gtr:description>JPND France</gtr:description><gtr:id>45E80164-5F37-4667-9E1D-907C24D03B80</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Collection of data acquired by RT-QuIC</gtr:partnerContribution><gtr:piContribution>We have trained scientists from the Department in the use of RT-QuIC</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interview on the Americal radio station  National Public Radio to dicsuss the impact of RT-QuIC on teh diagnosis of neurodegenerative diseases</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C9DD301C-821B-4FEE-BE4F-405326E7F61D</gtr:id><gtr:impact>This was a radio interview with myself and Dr Byron Caughey from the NIH, Rocky Mountain Laboratories, Montana, USA about the impact that RT-QuIC has had on the diagnosis of CJD and the potential use in other neurodegenerative diseases.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.npr.org/sections/health-shots/2017/02/06/508241181/prion-test-for-rare-fatal-brain-disease-helps-families-cope</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Guest speaker at APPS</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D492E779-76BE-4010-9CA5-32F68F7E3B9B</gtr:id><gtr:impact>Asian Pacific Prion Symposium, July 21-22nd 2013, CSF RT-QuIC in the diagnosis of sporadic CJD. This presentation described the results from the retrospective and prospective audit into the clinical utility of CSF RT-QuIC in the diagnosis of sporadic CJD. It also described the analytical factors that may influence the performance of this test. 

This meeting was attended by approximately 100 scientists and clinicians from the Asian-Pacific region who are studying the clinical and scientific aspects of prion disease.

Increased the collaboration between the NCJDRSU and the prion research community within Japan</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EFNS Neurology Conference (Istanbul, Turkey)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>840A00C6-E8FD-4613-832B-51A9349F7D00</gtr:id><gtr:impact>Between 50-100 neurologists and scientists attended a talk regarding the use of RT-QuIC in the diagnosis of sporadic CJD. There was general discussion afterwards about the utility of this approach to other protein mis-folding disorders.

None that I am aware of.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RT-QuIC ring-trial presentation at EuroCJD Experts Meeting, Budapest 17th-18th September 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C6D05305-1C9A-4FB0-BC40-81D8AC22853A</gtr:id><gtr:impact>Presentation of the data obtained from 2 International ring-trials for CSF RT-QuIC. The data obtained showed that RT-QuIC was a reliable and robust test for sCJD.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RT-QuiC Workshop 27th-28th April 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4AF15486-C60F-482B-94E9-B7289F940B1E</gtr:id><gtr:impact>RT-QuIC workshop was held at the National CJD Research &amp;amp; Surveillance Unit, University of Edinburgh on 27th-28th April 2015 and was funded by the European Centre for Disease Control (ECDC). It was aimed to inform scientists and clinicians from European laboratories and hospitals in the analytical, technical and clinical aspects of RT-QuIC analysis and interpretation. The feed back was positive and at least one centre has subsequently established RT-QuIC analysis.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STN Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4412D39B-828E-4564-B87C-44DD00C3220E</gtr:id><gtr:impact>I gave a presentation entitled RT-QuIC as a CSF test for CJD at the annual Scottish TSE Network. This presentation helped confirm the NCJDRSU as a centre of excellency for RT-QuIC analysis.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.stn.ed.ac.uk/stn/Seminars14.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Alliance Biosecure</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Alliance Bisecure</gtr:fundingOrg><gtr:id>2F4B1F19-F7A0-4AF4-BF8C-346830509BF2</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>224966</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Chief Scientist Office (CSO)</gtr:department><gtr:description>Chief Scientists Office</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Scottish Government</gtr:fundingOrg><gtr:id>C994B9AA-03FB-4DFF-BF2F-57C3D03E0EA5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Positive CSF RT-QuIC has been included into the diagnostic criteria for sporadic Creutzfeldt-Jakob disease</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DBA690F3-94AF-46EF-ACA8-032639BAF40F</gtr:id><gtr:impact>The inclusion of a positive RT-QuIC in the diagnostic criteria for sporadic CJD improves the accuracy of the clinical diagnosis of sporadic CJD, as the specificity of RT-QuIC has been shown by a number of international studies to have a specificity approaching 100%. It also enables patients who would previously been diagnosed with possible sporadic CJD to be diagnosed as probable sCJD. In addition, as sporadic CJD is a rapidly progressing disease, many patients die within weeks of onset of disease and a positive CSF RT-QuIC may be the only investigation. In this situation, a positive RT-QuIC enables these patients to be diagnosed with a high degree of accuracy and to be included in surveillance data. Therefore in summary the inclusion of a positive RT-QuIC in the diagnostic criteria improves clinical diagnosis and enhances epidemiological surveillance.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.cjd.ed.ac.uk/sites/default/files/criteria_0.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We produce full-length hamster rPrP as a reagent for the use in diagnostic RT-QuIC analysis. We are not seeking funding for this but will enlist a cost-recovery program to cover our costs.</gtr:description><gtr:id>896D0226-EEDA-4535-8141-40CC54F7DFB3</gtr:id><gtr:impact>We have supplied full-length hamster rPrP to laboratories throughout Europe including France, Italy, Spain, Netherlands, Sweden, Switzerland and Hungary. This has supported the introduction and evaluation of CSF RT-QuIC in each of these countries.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Supply of recombinant full-length hmaster rPrP for diagnostic use to European laboratories for use in diagnostic RT-QuIC analysis</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This database is an excel spreadsheet which collates both analytical and clinical data for RT-QuIC analysis from 9 international centres involved with CSF RT-QuIC analysis.</gtr:description><gtr:id>8F8DCE9E-8957-44A4-AD88-5C130F83D202</gtr:id><gtr:impact>This database will enable us to investigate both clinical and analytical factors that influence the sensitivity of RT-QuIC as a diagnostic test for sporadic CJD. As CJD is a rare disease without collating data from a number of different centres these factors may not be identified.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>European RT-QuIC Database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Cerebrospinal fluid samples from patients with and without CJD have been supplied to collaborators listed in Collaborations</gtr:description><gtr:id>F502BEAD-91BE-4D98-BD23-11EAAA385FDF</gtr:id><gtr:impact>This is a crucial aspect of ensuring the RT-QuIC technique is harmonised throughout Europe</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>JPND CSF ring trial</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Recombinant PrP is a major reagent in the RT-QuIC technique and is being used as the gold standard</gtr:description><gtr:id>5C8E73F8-3B57-46A0-BB99-DAE5658D40C6</gtr:id><gtr:impact>The supply of this regeant has ensured that the RT-QuIC technique has been readily established by all collaborators</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>JPND Supply of recombinant PrP</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/69C25C96-3052-4454-8749-C41DE86C907A"><gtr:id>69C25C96-3052-4454-8749-C41DE86C907A</gtr:id><gtr:title>Cerebrospinal fluid real-time quaking-induced conversion is a robust and reliable test for sporadic creutzfeldt-jakob disease: An international study.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b1a7e1889527d08d5d09d5b6bb063b8"><gtr:id>2b1a7e1889527d08d5d09d5b6bb063b8</gtr:id><gtr:otherNames>McGuire LI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4EC0AF37-B2DD-4710-9D34-7B059EE74FC1"><gtr:id>4EC0AF37-B2DD-4710-9D34-7B059EE74FC1</gtr:id><gtr:title>Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking-induced conversion.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/920ed8da3cbaa75e635c785b4cc316d8"><gtr:id>920ed8da3cbaa75e635c785b4cc316d8</gtr:id><gtr:otherNames>Peden AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03F1EE95-890A-4D5C-A986-3AF6CDDC28FF"><gtr:id>03F1EE95-890A-4D5C-A986-3AF6CDDC28FF</gtr:id><gtr:title>Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b1a7e1889527d08d5d09d5b6bb063b8"><gtr:id>2b1a7e1889527d08d5d09d5b6bb063b8</gtr:id><gtr:otherNames>McGuire LI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4414970-9809-4675-9167-06C0A674597A"><gtr:id>C4414970-9809-4675-9167-06C0A674597A</gtr:id><gtr:title>Prion protein aggregation assays in the diagnosis of human prion diseases</gtr:title><gtr:parentPublicationTitle>Future Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e4e5e248878a874673b0e17efd75d4d0"><gtr:id>e4e5e248878a874673b0e17efd75d4d0</gtr:id><gtr:otherNames>Green A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>14796708</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF67EC88-8E1C-4A2A-8A09-143D0721183A"><gtr:id>EF67EC88-8E1C-4A2A-8A09-143D0721183A</gtr:id><gtr:title>Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and A?42 levels.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7da65cdd4c3bc3ccba56b748ba74955f"><gtr:id>7da65cdd4c3bc3ccba56b748ba74955f</gtr:id><gtr:otherNames>Lattanzio F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J016071/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>